Drachenberg Cinthia B, Hirsch Hans H, Papadimitriou John C, Gosert Rainer, Wali Ravinder K, Munivenkatappa Raghava, Nogueira Joseph, Cangro Charles B, Haririan Abdolreza, Mendley Susan, Ramos Emilio
Department of Pathology, Medicine and Pediatrics, University of Maryland, School of Medicine, Baltimore, MD 21201, USA.
Transplantation. 2007 Aug 15;84(3):323-30. doi: 10.1097/01.tp.0000269706.59977.a5.
JC virus (JCV) viruria is more common than BK virus (BKV) viruria in healthy individuals but in kidney transplants (KT), polyomavirus nephropathy (PVAN) is primarily caused by BKV. Few cases of PVAN have been attributed to JCV. Systematic studies on JCV replication in KT are lacking.
Out of a cohort of KT patients screened with urine cytology, patients shedding decoy cells were studied (n=103). Molecular studies demonstrated BKV, JCV, or BKV+JCV shedding in 58 (56.3%), 28 (27.2%), and 17 (16.5%), respectively. Biopsy was performed when decoy cells persisted 2 months or serum creatinine increased >20%.
BKV viruria was strongly associated with BKV viremia (93%), PVAN (48%, P=0.01) and graft loss (P=0.03). Higher BKV viremia correlated with graft dysfunction (P=0.01), more advanced histological pattern of PVAN (P<0.0001), and more infected cells in biopsy (P=0.0001). BKV viremia of > or =10,000 copies/mL was significantly associated with histologically confirmed PVAN (P=0.0001). Reduction of immunosuppression lead to disappearance of decoy cells in patients shedding BK (>93%). JCV viruria, was more often asymptomatic (P=0.002) and affected older patients (P=0.02). JCV PVAN was less common (21.4%) and was characterized by sparse cytopathic changes but significant inflammation and fibrosis. JCV viremia was rare (14.2%), transient, and low (mean 2.0E+03/mL). After reduction of immunosuppression decoy cells persisted in >50% of patients with JCV (P=0.0001), but no graft loss occurred. During the period of the current study, the incidence of BKV-PVAN was 5.5% and the incidence of JCV-PVAN was 0.9%.
The data point to significant differences of BKV and JCV biology regarding replication and disease in KT patients, with important implications for screening and management.
在健康个体中,JC病毒(JCV)病毒尿比BK病毒(BKV)病毒尿更常见,但在肾移植(KT)受者中,多瘤病毒肾病(PVAN)主要由BKV引起。很少有PVAN病例归因于JCV。目前缺乏关于JCV在KT受者中复制情况的系统性研究。
在一组接受尿细胞学筛查的KT患者中,对脱落诱饵细胞的患者进行研究(n = 103)。分子研究显示,分别有58例(56.3%)、28例(27.2%)和17例(16.5%)患者出现BKV、JCV或BKV + JCV病毒脱落。当诱饵细胞持续存在2个月或血清肌酐升高>20%时进行活检。
BKV病毒尿与BKV病毒血症(93%)、PVAN(48%,P = 0.01)和移植肾失功(P = 0.03)密切相关。较高的BKV病毒血症与移植肾功能障碍(P = 0.01)、PVAN更严重的组织学表现(P < 0.0001)以及活检中更多的感染细胞(P = 0.0001)相关。BKV病毒血症≥10,000拷贝/mL与组织学确诊的PVAN显著相关(P = 0.0001)。减少免疫抑制可使BK病毒脱落患者(>93%)的诱饵细胞消失。JCV病毒尿通常无症状(P = 0.002),且多见于老年患者(P = 0.02)。JCV - PVAN较少见(21.4%),其特征为细胞病变改变稀疏,但有明显炎症和纤维化。JCV病毒血症罕见(14.2%),呈一过性且水平较低(平均2.0E + 03/mL)。减少免疫抑制后,>50%的JCV病毒脱落患者的诱饵细胞持续存在(P = 0.0001),但未发生移植肾失功。在本研究期间,BKV - PVAN的发生率为5.5%,JCV - PVAN的发生率为0.9%。
数据表明BKV和JCV在KT患者的复制及疾病方面存在显著生物学差异,这对筛查和管理具有重要意义。